Latest news with #KGaA
Business Insider
27-06-2025
- Business
- Business Insider
Kepler Capital Sticks to Its Hold Rating for Carl Zeiss Meditec (0DHC)
In a report released on June 25, Oliver Reinberg from Kepler Capital maintained a Hold rating on Carl Zeiss Meditec (0DHC – Research Report), with a price target of €59.00. The company's shares closed last Wednesday at €57.65. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Reinberg is an analyst with an average return of -5.5% and a 40.82% success rate. Reinberg covers the Healthcare sector, focusing on stocks such as Carl Zeiss Meditec, Draegerwerk AG & Co. KGaA, and Fresenius Medical Care AG & Co. KGaA. Carl Zeiss Meditec has an analyst consensus of Hold, with a price target consensus of €64.17.
Business Insider
30-05-2025
- Business
- Business Insider
Kepler Capital Reaffirms Their Hold Rating on Elekta AB (0O5H)
Kepler Capital analyst Oliver Reinberg maintained a Hold rating on Elekta AB (0O5H – Research Report) on May 28 and set a price target of SEK64.00. The company's shares closed last Wednesday at SEK52.65. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Reinberg is an analyst with an average return of -5.2% and a 40.69% success rate. Reinberg covers the Healthcare sector, focusing on stocks such as Fresenius SE & Co. KGaA, Draegerwerk AG & Co. KGaA, and Fresenius Medical Care AG & Co. KGaA. In addition to Kepler Capital , Elekta AB also received a Hold from Danske Bank's Erik Cassel in a report issued on May 21. However, yesterday, Barclays maintained a Sell rating on Elekta AB (LSE: 0O5H).
Yahoo
19-05-2025
- Business
- Yahoo
CTS Eventim KGaA's (ETR:EVD) 27% CAGR outpaced the company's earnings growth over the same five-year period
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on a lighter note, a good company can see its share price rise well over 100%. For instance, the price of CTS Eventim AG & Co. KGaA (ETR:EVD) stock is up an impressive 213% over the last five years. It's also up 15% in about a month. But this could be related to good market conditions -- stocks in its market are up 9.0% in the last month. The past week has proven to be lucrative for CTS Eventim KGaA investors, so let's see if fundamentals drove the company's five-year performance. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. To quote Buffett, 'Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace...' By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time. Over half a decade, CTS Eventim KGaA managed to grow its earnings per share at 19% a year. This EPS growth is lower than the 26% average annual increase in the share price. So it's fair to assume the market has a higher opinion of the business than it did five years ago. And that's hardly shocking given the track record of growth. The image below shows how EPS has tracked over time (if you click on the image you can see greater detail). We know that CTS Eventim KGaA has improved its bottom line over the last three years, but what does the future have in store? Take a more thorough look at CTS Eventim KGaA's financial health with this free report on its balance sheet. As well as measuring the share price return, investors should also consider the total shareholder return (TSR). Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. As it happens, CTS Eventim KGaA's TSR for the last 5 years was 224%, which exceeds the share price return mentioned earlier. The dividends paid by the company have thusly boosted the total shareholder return. We're pleased to report that CTS Eventim KGaA shareholders have received a total shareholder return of 40% over one year. That's including the dividend. Since the one-year TSR is better than the five-year TSR (the latter coming in at 27% per year), it would seem that the stock's performance has improved in recent times. Given the share price momentum remains strong, it might be worth taking a closer look at the stock, lest you miss an opportunity. It's always interesting to track share price performance over the longer term. But to understand CTS Eventim KGaA better, we need to consider many other factors. Consider for instance, the ever-present spectre of investment risk. We've identified 1 warning sign with CTS Eventim KGaA , and understanding them should be part of your investment process. If you are like me, then you will not want to miss this free list of undervalued small caps that insiders are buying. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on German exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
18-05-2025
- Business
- Yahoo
Analysts Have Made A Financial Statement On thyssenkrupp nucera AG & Co. KGaA's (ETR:NCH2) Second-Quarter Report
It's been a sad week for thyssenkrupp nucera AG & Co. KGaA (ETR:NCH2), who've watched their investment drop 12% to €8.73 in the week since the company reported its second-quarter result. Revenues were €216m, with thyssenkrupp nucera KGaA reporting some 2.0% below analyst expectations. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. Following the recent earnings report, the consensus from eleven analysts covering thyssenkrupp nucera KGaA is for revenues of €895.7m in 2025. This implies a discernible 7.6% decline in revenue compared to the last 12 months. Statutory earnings per share are expected to nosedive 62% to €0.072 in the same period. Yet prior to the latest earnings, the analysts had been anticipated revenues of €890.3m and earnings per share (EPS) of €0.072 in 2025. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results. Check out our latest analysis for thyssenkrupp nucera KGaA It will come as no surprise then, to learn that the consensus price target is largely unchanged at €12.30. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. There are some variant perceptions on thyssenkrupp nucera KGaA, with the most bullish analyst valuing it at €17.00 and the most bearish at €8.50 per share. This is a fairly broad spread of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the business. Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. These estimates imply that revenue is expected to slow, with a forecast annualised decline of 15% by the end of 2025. This indicates a significant reduction from annual growth of 33% over the last year. Compare this with our data, which suggests that other companies in the same industry are, in aggregate, expected to see their revenue grow 4.0% per year. It's pretty clear that thyssenkrupp nucera KGaA's revenues are expected to perform substantially worse than the wider industry. The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates. Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have forecasts for thyssenkrupp nucera KGaA going out to 2027, and you can see them free on our platform here. Even so, be aware that thyssenkrupp nucera KGaA is showing 1 warning sign in our investment analysis , you should know about... Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
18-05-2025
- Business
- Yahoo
Analysts Have Made A Financial Statement On thyssenkrupp nucera AG & Co. KGaA's (ETR:NCH2) Second-Quarter Report
It's been a sad week for thyssenkrupp nucera AG & Co. KGaA (ETR:NCH2), who've watched their investment drop 12% to €8.73 in the week since the company reported its second-quarter result. Revenues were €216m, with thyssenkrupp nucera KGaA reporting some 2.0% below analyst expectations. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. Following the recent earnings report, the consensus from eleven analysts covering thyssenkrupp nucera KGaA is for revenues of €895.7m in 2025. This implies a discernible 7.6% decline in revenue compared to the last 12 months. Statutory earnings per share are expected to nosedive 62% to €0.072 in the same period. Yet prior to the latest earnings, the analysts had been anticipated revenues of €890.3m and earnings per share (EPS) of €0.072 in 2025. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results. Check out our latest analysis for thyssenkrupp nucera KGaA It will come as no surprise then, to learn that the consensus price target is largely unchanged at €12.30. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. There are some variant perceptions on thyssenkrupp nucera KGaA, with the most bullish analyst valuing it at €17.00 and the most bearish at €8.50 per share. This is a fairly broad spread of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the business. Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. These estimates imply that revenue is expected to slow, with a forecast annualised decline of 15% by the end of 2025. This indicates a significant reduction from annual growth of 33% over the last year. Compare this with our data, which suggests that other companies in the same industry are, in aggregate, expected to see their revenue grow 4.0% per year. It's pretty clear that thyssenkrupp nucera KGaA's revenues are expected to perform substantially worse than the wider industry. The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates. Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have forecasts for thyssenkrupp nucera KGaA going out to 2027, and you can see them free on our platform here. Even so, be aware that thyssenkrupp nucera KGaA is showing 1 warning sign in our investment analysis , you should know about... Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
